Mehdi Azizmohammad Looha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehdi Azizmohammad Looha has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
- Amir Sadeghi
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran
5 shared publications - Elaheh Zarean
Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
5 shared publications - Mohammad Esmaeil Akbari
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 shared publications - Mohamad Amin Pourhoseingholi
NIHR Nottingham Biomedical Research Centre, Nottingham NG1 5DU, UK
4 shared publications - Soheila Khodakarim
Department of Biostatistics Shiraz University of Medical Sciences Shiraz Iran
4 shared publications - Atieh Akbari
Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in BMC Pediatrics
Hearing impairment and ototoxic medication exposure in children with cystic fibrosis: a multicenter cross-sectional study
Purpose: To estimate the prevalence of hearing impairment and explore its associations with demographic, clinical, and medication-use characteristics in Iranian children and adolescents with cystic fibrosis (CF). Methods: This multicenter cross-sectional study included 193 participants younger than 18 years before age rounding with a documented clinical diagnosis of CF in Lorestan, Kerman, and Khuzestan during 2023–2024. Hearing status was obtained from audiological reports under an operational ≥30 dB definition. Medication use was recorded as binary indicators without route-specific or cumulative exposure information. Group comparisons used exact conditional Wilcoxon rank-sum and Fisher exact tests. Exploratory associations were estimated using univariable Firth penalized logistic regression. Results: Median age was 12.00 years (IQR, 11.00–14.00), and 107 participants (55.4%) were female. Six participants had hearing impairment, giving a prevalence of 3.1% (exact 95% CI, 1.1%–6.6%); all six were classified as having mild sensorineural loss. Impairment occurred in 6 of 64 participants with tobramycin use and none of 129 without use. The Firth estimate suggested an association (OR, 28.78; profile penalized-likelihood 95% CI, 3.31–3776.23; P < 0.001), with substantial imprecision. The azithromycin comparison was inconclusive. Conclusion: Hearing impairment was uncommon under the study definition. The exploratory, unadjusted tobramycin association does not establish causation or a route-specific effect. Larger prospective multicenter studies with detailed medication exposure histories and baseline and repeated hearing assessments are needed.
- 31 October 2026
- Published by Springer Nature in BMC Pediatrics
Open AccessHearing impairment and ototoxic medication exposure in children with cystic fibrosis: a multicenter cross-sectional study
Purpose: To estimate the prevalence of hearing impairment and explore its associations with demographic, clinical, and medication-use characteristics in Iranian children and adolescents with cystic fibrosis (CF). Methods: This multicenter cross-sectional study included 193 participants younger than 18 years before age rounding with a documented clinical diagnosis of CF in Lorestan, Kerman, and Khuzestan during 2023–2024. Hearing status was obtained from audiological reports under an operational ≥30 dB definition. Medication use was recorded as binary indicators without route-specific or cumulative exposure information. Group comparisons used exact conditional Wilcoxon rank-sum and Fisher exact tests. Exploratory associations were estimated using univariable Firth penalized logistic regression. Results: Median age was 12.00 years (IQR, 11.00–14.00), and 107 participants (55.4%) were female. Six participants had hearing impairment, giving a prevalence of 3.1% (exact 95% CI, 1.1%–6.6%); all six were classified as having mild sensorineural loss. Impairment occurred in 6 of 64 participants with tobramycin use and none of 129 without use. The Firth estimate suggested an association (OR, 28.78; profile penalized-likelihood 95% CI, 3.31–3776.23; P < 0.001), with substantial imprecision. The azithromycin comparison was inconclusive. Conclusion: Hearing impairment was uncommon under the study definition. The exploratory, unadjusted tobramycin association does not establish causation or a route-specific effect. Larger prospective multicenter studies with detailed medication exposure histories and baseline and repeated hearing assessments are needed.
- Open Access
- 22 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11) , e73373
Beyond Pigmentation: Interplay of Metabolic Profile, Carotid Intima—Media Thickness, and Fatty Liver in Vitiligo: An Age‐ and Sex‐Matched Case‐Control Study
Background and Aims: Vitiligo shares inflammatory and metabolic pathways with cardiovascular and hepatic steatosis. Carotid intima–media thickness (IMT) is an established marker of early subclinical atherosclerosis, whereas non‐alcoholic fatty liver disease (NAFLD) reflects hepatic involvement in chronic inflammatory and metabolic dysregulation. This study aimed to evaluate subclinical vascular and hepatic changes in patients with vitiligo and to explore their associations with disease characteristics and metabolic parameters. Methods: In this age‐ and sex‐matched case‐control study, adults with mild vitiligo (Vitiligo Area Severity Index [VASI] < 5%) and no metabolic syndrome were compared with healthy controls. Participants underwent carotid duplex ultrasonography to assess common carotid IMT and atherosclerotic plaques, liver ultrasonography for steatosis grading, and laboratory testing, including lipid profile (total cholesterol, low‐density lipoprotein [LDL], high‐density lipoprotein [HDL], and triglycerides [TG]), fasting blood glucose (FBS), and body mass index (BMI). Disease duration and VASI score were also assessed. Results: A total of 46 participants (23 patients with vitiligo and 23 healthy controls) completed all assessments. Common carotid IMT measurements and liver ultrasound findings were comparable between groups. However, abnormal HDL levels were more frequent among patients with vitiligo (69.6% vs. 39.1%, p = 0.03). Greater disease severity, measured by VASI score, and higher BMI were independently associated with increased right carotid IMT ( p = 0.01, 0.02, respectively). Exploratory interaction analyses demonstrated significant sex‐dependent associations of HDL, triglycerides, and fatty liver status with carotid IMT. Post hoc analyses identified higher carotid IMT among male patients with abnormal HDL. Conclusion: Selected subgroups of patients with vitiligo, particularly men with HDL metabolic abnormalities, may exhibit differences in subclinical carotid atherosclerosis. Disease severity and BMI may also contribute to the vascular risk. Although exploratory, these findings warrant further investigation of cardiovascular and hepatic risk profiles in selected patients with vitiligo.
- 22 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11) , e73373
Open AccessBeyond Pigmentation: Interplay of Metabolic Profile, Carotid Intima—Media Thickness, and Fatty Liver in Vitiligo: An Age‐ and Sex‐Matched Case‐Control Study
Background and Aims: Vitiligo shares inflammatory and metabolic pathways with cardiovascular and hepatic steatosis. Carotid intima–media thickness (IMT) is an established marker of early subclinical atherosclerosis, whereas non‐alcoholic fatty liver disease (NAFLD) reflects hepatic involvement in chronic inflammatory and metabolic dysregulation. This study aimed to evaluate subclinical vascular and hepatic changes in patients with vitiligo and to explore their associations with disease characteristics and metabolic parameters. Methods: In this age‐ and sex‐matched case‐control study, adults with mild vitiligo (Vitiligo Area Severity Index [VASI] < 5%) and no metabolic syndrome were compared with healthy controls. Participants underwent carotid duplex ultrasonography to assess common carotid IMT and atherosclerotic plaques, liver ultrasonography for steatosis grading, and laboratory testing, including lipid profile (total cholesterol, low‐density lipoprotein [LDL], high‐density lipoprotein [HDL], and triglycerides [TG]), fasting blood glucose (FBS), and body mass index (BMI). Disease duration and VASI score were also assessed. Results: A total of 46 participants (23 patients with vitiligo and 23 healthy controls) completed all assessments. Common carotid IMT measurements and liver ultrasound findings were comparable between groups. However, abnormal HDL levels were more frequent among patients with vitiligo (69.6% vs. 39.1%, p = 0.03). Greater disease severity, measured by VASI score, and higher BMI were independently associated with increased right carotid IMT ( p = 0.01, 0.02, respectively). Exploratory interaction analyses demonstrated significant sex‐dependent associations of HDL, triglycerides, and fatty liver status with carotid IMT. Post hoc analyses identified higher carotid IMT among male patients with abnormal HDL. Conclusion: Selected subgroups of patients with vitiligo, particularly men with HDL metabolic abnormalities, may exhibit differences in subclinical carotid atherosclerosis. Disease severity and BMI may also contribute to the vascular risk. Although exploratory, these findings warrant further investigation of cardiovascular and hepatic risk profiles in selected patients with vitiligo.
- 11 June 2026
- Published by Springer Nature in Pediatric Research
Digestive congenital anomalies: a call for equity in global neonatal surgical care
The global burden of digestive congenital anomalies (DCAs) remains significant, with the recent analysis by Cai et al. highlighting both progress and profound inequities. The disease burden is concentrated in the neonatal period, where the first days of life are a critical window for survival. Optimal outcomes depend on a seamless continuum of care: prenatal diagnosis, delivery at a specialized tertiary center, and immediate postnatal surgery. However, stark disparities in access to this care persist. In high-income countries, multidisciplinary management leads to high survival, while in low- and middle-income countries, delays and limited surgical capacity result in preventable mortality. Beyond treatment, preventive public health measures like maternal nutrition and folate supplementation are crucial. To bridge this equity gap, we must invest in neonatal surgical capacity, integrate DCA care into universal health coverage, and strengthen birth defect surveillance. Ensuring that every newborn with a correctable digestive anomaly has a chance to survive requires coordinated global action to make timely, life-saving surgery accessible to all.
- 11 June 2026
- Published by Springer Nature in Pediatric Research
Digestive congenital anomalies: a call for equity in global neonatal surgical care
The global burden of digestive congenital anomalies (DCAs) remains significant, with the recent analysis by Cai et al. highlighting both progress and profound inequities. The disease burden is concentrated in the neonatal period, where the first days of life are a critical window for survival. Optimal outcomes depend on a seamless continuum of care: prenatal diagnosis, delivery at a specialized tertiary center, and immediate postnatal surgery. However, stark disparities in access to this care persist. In high-income countries, multidisciplinary management leads to high survival, while in low- and middle-income countries, delays and limited surgical capacity result in preventable mortality. Beyond treatment, preventive public health measures like maternal nutrition and folate supplementation are crucial. To bridge this equity gap, we must invest in neonatal surgical capacity, integrate DCA care into universal health coverage, and strengthen birth defect surveillance. Ensuring that every newborn with a correctable digestive anomaly has a chance to survive requires coordinated global action to make timely, life-saving surgery accessible to all.
- Open Access
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 386-397
Impact of body mass index on the outcomes of endoscopic retrograde cholangiopancreatography: a systematic review and network meta-analysis
Background/Aims: Obesity is an increasing health concern worldwide, and an elevated body mass index (BMI) may influence the outcomes of endoscopic retrograde cholangiopancreatography (ERCP). This systematic review and network meta-analysis aimed to investigate the association between BMI and ERCP outcomes.Methods: A systematic search was performed using PubMed, Scopus, and Web of Science to identify relevant studies that reported clinical outcomes of ERCP in different BMI groups. Patients were categorized into five BMI-based following groups: underweight (BMI<18.5 kg/m²), normal weight (18.5 kg/m²≤BMI<25 kg/m²), overweight (25 kg/m²≤BMI<30 kg/m²), obesity (30 kg/m²≤BMI0.05). Moreover, the BMI groups had similar rates of difficult cannulation, successful cannulation, complete stone extraction, and procedural success.Conclusions: ERCP success and adverse events were similar among different BMI groups. Neither an elevated nor a low BMI was associated with an increased risk of PEP. Further large-scale prospective studies are required to validate these findings.
- 30 May 2026
- Published by The Korean Society of Gastrointestinal Endoscopy in Clinical Endoscopy
- Vol. 59 (3) , 386-397
Open AccessImpact of body mass index on the outcomes of endoscopic retrograde cholangiopancreatography: a systematic review and network meta-analysis
Background/Aims: Obesity is an increasing health concern worldwide, and an elevated body mass index (BMI) may influence the outcomes of endoscopic retrograde cholangiopancreatography (ERCP). This systematic review and network meta-analysis aimed to investigate the association between BMI and ERCP outcomes.Methods: A systematic search was performed using PubMed, Scopus, and Web of Science to identify relevant studies that reported clinical outcomes of ERCP in different BMI groups. Patients were categorized into five BMI-based following groups: underweight (BMI<18.5 kg/m²), normal weight (18.5 kg/m²≤BMI<25 kg/m²), overweight (25 kg/m²≤BMI<30 kg/m²), obesity (30 kg/m²≤BMI0.05). Moreover, the BMI groups had similar rates of difficult cannulation, successful cannulation, complete stone extraction, and procedural success.Conclusions: ERCP success and adverse events were similar among different BMI groups. Neither an elevated nor a low BMI was associated with an increased risk of PEP. Further large-scale prospective studies are required to validate these findings.
- Open Access
- 3 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5)
Diagnostic Efficacy and Clinical Aspects of Panoramic‐View Versus Forward‐View Capsule Endoscopy for Suspected Small Bowel Bleeding: A Systematic Review and Meta‐Analysis
Background and Aims: CapsoCam provides a 360° panoramic‐view in capsule endoscopy (CE). This study aimed to conduct the initial systematic review and meta‐analysis on the diagnostic efficacy and clinical aspects of CapsoCam in patients with Suspected small bowel bleeding (SSBB), potentially comparing it to forward‐view CE. Methods: A systematic search of PubMed, Embase, and Scopus databases was performed for human studies reporting outcomes of interest up to January 2025. Titles and abstracts were screened, and full‐texts were selected based on predefined inclusion criteria by two reviewers. The quality assessment used Joanna Briggs Institute checklist. Meta‐analysis used a random‐effects model with a 95% confidence interval (CI). Publication bias was evaluated using Egger and Begg's tests. A leave‐one‐out sensitivity analysis was performed. Results: Five studies met the inclusion criteria. The meta‐analysis revealed no statistically significant difference in diagnostic yield between the two CE types in cases of SSBB ( p = 0.89, 95% CI: −0.08 to 0.09). Egger's test and Begg's test showed no significant publication bias. Comparative analysis between panoramic and forward‐view CEs demonstrated similar performance for small bowel transit time ( p = 0.58, 95% CI: −0.33 to 0.59), although evaluation time was significantly longer with CapsoCam ( p = 0.001, 95% CI: 0.42 to 1.60). The risk difference in completion rates was not statistically significant ( p = 0.91, 95% CI: −0.13 to 0.15). Subgroup analyses showed no significant differences in diagnostic yield or other outcomes between CapsoCam PLUS and SV‐1, or by study design. Conclusion: Our analysis suggests that CapsoCam demonstrates comparable performance to forward‐view CE in terms of diagnostic reliability, clinical efficacy, and safety profile, except for reading time. However, the limited number of studies underscores the need for further research to validate CapsoCam's usability in routine clinical practice for SSBB patients compared to forward‐view CE.
- 3 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5)
Open AccessDiagnostic Efficacy and Clinical Aspects of Panoramic‐View Versus Forward‐View Capsule Endoscopy for Suspected Small Bowel Bleeding: A Systematic Review and Meta‐Analysis
Background and Aims: CapsoCam provides a 360° panoramic‐view in capsule endoscopy (CE). This study aimed to conduct the initial systematic review and meta‐analysis on the diagnostic efficacy and clinical aspects of CapsoCam in patients with Suspected small bowel bleeding (SSBB), potentially comparing it to forward‐view CE. Methods: A systematic search of PubMed, Embase, and Scopus databases was performed for human studies reporting outcomes of interest up to January 2025. Titles and abstracts were screened, and full‐texts were selected based on predefined inclusion criteria by two reviewers. The quality assessment used Joanna Briggs Institute checklist. Meta‐analysis used a random‐effects model with a 95% confidence interval (CI). Publication bias was evaluated using Egger and Begg's tests. A leave‐one‐out sensitivity analysis was performed. Results: Five studies met the inclusion criteria. The meta‐analysis revealed no statistically significant difference in diagnostic yield between the two CE types in cases of SSBB ( p = 0.89, 95% CI: −0.08 to 0.09). Egger's test and Begg's test showed no significant publication bias. Comparative analysis between panoramic and forward‐view CEs demonstrated similar performance for small bowel transit time ( p = 0.58, 95% CI: −0.33 to 0.59), although evaluation time was significantly longer with CapsoCam ( p = 0.001, 95% CI: 0.42 to 1.60). The risk difference in completion rates was not statistically significant ( p = 0.91, 95% CI: −0.13 to 0.15). Subgroup analyses showed no significant differences in diagnostic yield or other outcomes between CapsoCam PLUS and SV‐1, or by study design. Conclusion: Our analysis suggests that CapsoCam demonstrates comparable performance to forward‐view CE in terms of diagnostic reliability, clinical efficacy, and safety profile, except for reading time. However, the limited number of studies underscores the need for further research to validate CapsoCam's usability in routine clinical practice for SSBB patients compared to forward‐view CE.
- Open Access
- 29 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5)
Trends in Meningitis Burden and Projections to 2040: A Secondary Analysis of the Global Burden of Disease Study 2023
Background and Aims: Meningitis remains a global health challenge, characterized by substantial regional and etiologic disparities. This study aimed to analyze recent trends, forecast future burden, and examine the influence of development status on meningitis outcomes. Methods: We used Global Burden of Disease 2023 data to assess trends in age‐standardized incidence rate (ASIR), age‐standardized disability‐adjusted life‐year (DALY) rate (ASDR), and age‐standardized mortality rate (ASMR) for meningitis from 1990 to 2023 across regions and major etiologies. Temporal trends were assessed using joinpoint regression. Future projections through 2040 were generated using a hybrid time‐series model. Development‐related disparities were explored using multilevel regression based on the Human Development Index (HDI), and spatial clustering was analyzed. Results: From 1990 to 2023, global meningitis burden declined markedly, with ASIR, ASDR, and ASMR decreasing by roughly half. Despite these improvements, Sub‐Saharan Africa remained the most affected region in 2023, showing the highest ASIR, ASDR, and ASMR and the smallest proportional declines. Etiology‐specific analyses demonstrated substantial heterogeneity. Among bacterial causes, Streptococcus pneumoniae and Neisseria meningitidis remain the leading global contributors, while Haemophilus influenzae showed the steepest long‐term reductions. Viral meningitis was primarily driven by non‐polio enteroviruses, whereas Candida spp. represented the main fungal contributor. HDI‐based analyses revealed that although all development groups experienced declining trends, countries with higher HDI had consistently faster reductions across all three measures. Spatial clustering identified persistent high‐burden hotspots across the African meningitis belt. Projections to 2040 indicated continued global declines across all major etiologies, with S. pneumoniae expected to remain the predominant contributor and N. meningitidis showing the largest relative reductions. Conclusion: Despite substantial global declines, meningitis remains unevenly distributed, especially in Sub‐Saharan Africa, where incidence, DALY burden, and mortality remain highest. Projections show continued improvement, although Streptococcus pneumoniae is expected to remain the leading cause.
- 29 April 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5)
Open AccessTrends in Meningitis Burden and Projections to 2040: A Secondary Analysis of the Global Burden of Disease Study 2023
Background and Aims: Meningitis remains a global health challenge, characterized by substantial regional and etiologic disparities. This study aimed to analyze recent trends, forecast future burden, and examine the influence of development status on meningitis outcomes. Methods: We used Global Burden of Disease 2023 data to assess trends in age‐standardized incidence rate (ASIR), age‐standardized disability‐adjusted life‐year (DALY) rate (ASDR), and age‐standardized mortality rate (ASMR) for meningitis from 1990 to 2023 across regions and major etiologies. Temporal trends were assessed using joinpoint regression. Future projections through 2040 were generated using a hybrid time‐series model. Development‐related disparities were explored using multilevel regression based on the Human Development Index (HDI), and spatial clustering was analyzed. Results: From 1990 to 2023, global meningitis burden declined markedly, with ASIR, ASDR, and ASMR decreasing by roughly half. Despite these improvements, Sub‐Saharan Africa remained the most affected region in 2023, showing the highest ASIR, ASDR, and ASMR and the smallest proportional declines. Etiology‐specific analyses demonstrated substantial heterogeneity. Among bacterial causes, Streptococcus pneumoniae and Neisseria meningitidis remain the leading global contributors, while Haemophilus influenzae showed the steepest long‐term reductions. Viral meningitis was primarily driven by non‐polio enteroviruses, whereas Candida spp. represented the main fungal contributor. HDI‐based analyses revealed that although all development groups experienced declining trends, countries with higher HDI had consistently faster reductions across all three measures. Spatial clustering identified persistent high‐burden hotspots across the African meningitis belt. Projections to 2040 indicated continued global declines across all major etiologies, with S. pneumoniae expected to remain the predominant contributor and N. meningitidis showing the largest relative reductions. Conclusion: Despite substantial global declines, meningitis remains unevenly distributed, especially in Sub‐Saharan Africa, where incidence, DALY burden, and mortality remain highest. Projections show continued improvement, although Streptococcus pneumoniae is expected to remain the leading cause.
- Open Access
- 23 April 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Skeletal muscle index and hand grip strength as predictors of postoperative recovery in patients with gastrointestinal tumors
Background: Sarcopenia, defined by loss of muscle mass and function, predicts poor cancer outcomes. In gastrointestinal (GI) malignancies, its prognostic role remains underexplored. Skeletal muscle index (SMI) from computed tomography (CT) scans and hand grip strength (HGS) may contribute to preoperative risk assessment. This study aimed primarily to evaluate the association between preoperative SMI and postoperative hospitalization length, and secondarily to assess HGS as a functional measure related to muscle status and its association with SMI and other clinical factors in GI cancer patients. Methods: A prospective observational cohort study was conducted (2019–2022) at a tertiary hospital in Tehran. Patients with GI malignancies undergoing surgery and preoperative CT scans were included. SMI was measured at the L3 vertebral level using standardized thresholds. The primary outcome was hospitalization length; HGS was secondary. Negative binomial regression was used to evaluate predictors of hospitalization length, and linear regression models were used to examine factors associated with HGS. Univariate and multivariable analyses were performed. Results: A total of 233 patients were included in the study. The mean age was 59.13 ± 12.74 years, and 56.7% were male. Higher SMI was associated with shorter hospitalization length in both univariate and multivariable analyses (Incidence rate ratios [IRRs] = 0.97 and 0.94, respectively; P < 0.001). HGS was not associated with hospitalization length. Psoas muscle diameter showed a small positive association with hospitalization length in the multivariable model (IRR = 1.01; P = 0.032). SMI was positively associated with HGS in univariate analyses for both hands (right hand: β = 0.31; P = 0.027; left hand: β = 0.32; P = 0.016), but this association was not retained after adjustment. Age and psoas muscle diameter remained independent predictors of HGS in both hands. Conclusion: Preoperative SMI appears to be a clinically relevant imaging-based marker of postoperative recovery in patients with GI cancers and may contribute to preoperative risk assessment. HGS, evaluated as a functional measure of muscle status, was associated with SMI and selected clinical factors but did not provide comparable prognostic information for hospitalization outcomes. These findings support the complementary but distinct roles of structural (SMI) and functional (HGS) muscle assessments. Further studies are required to validate these findings and clarify their clinical application.
- 23 April 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessSkeletal muscle index and hand grip strength as predictors of postoperative recovery in patients with gastrointestinal tumors
Background: Sarcopenia, defined by loss of muscle mass and function, predicts poor cancer outcomes. In gastrointestinal (GI) malignancies, its prognostic role remains underexplored. Skeletal muscle index (SMI) from computed tomography (CT) scans and hand grip strength (HGS) may contribute to preoperative risk assessment. This study aimed primarily to evaluate the association between preoperative SMI and postoperative hospitalization length, and secondarily to assess HGS as a functional measure related to muscle status and its association with SMI and other clinical factors in GI cancer patients. Methods: A prospective observational cohort study was conducted (2019–2022) at a tertiary hospital in Tehran. Patients with GI malignancies undergoing surgery and preoperative CT scans were included. SMI was measured at the L3 vertebral level using standardized thresholds. The primary outcome was hospitalization length; HGS was secondary. Negative binomial regression was used to evaluate predictors of hospitalization length, and linear regression models were used to examine factors associated with HGS. Univariate and multivariable analyses were performed. Results: A total of 233 patients were included in the study. The mean age was 59.13 ± 12.74 years, and 56.7% were male. Higher SMI was associated with shorter hospitalization length in both univariate and multivariable analyses (Incidence rate ratios [IRRs] = 0.97 and 0.94, respectively; P < 0.001). HGS was not associated with hospitalization length. Psoas muscle diameter showed a small positive association with hospitalization length in the multivariable model (IRR = 1.01; P = 0.032). SMI was positively associated with HGS in univariate analyses for both hands (right hand: β = 0.31; P = 0.027; left hand: β = 0.32; P = 0.016), but this association was not retained after adjustment. Age and psoas muscle diameter remained independent predictors of HGS in both hands. Conclusion: Preoperative SMI appears to be a clinically relevant imaging-based marker of postoperative recovery in patients with GI cancers and may contribute to preoperative risk assessment. HGS, evaluated as a functional measure of muscle status, was associated with SMI and selected clinical factors but did not provide comparable prognostic information for hospitalization outcomes. These findings support the complementary but distinct roles of structural (SMI) and functional (HGS) muscle assessments. Further studies are required to validate these findings and clarify their clinical application.
- Open Access
- 21 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Effects of B vitamins and magnesium on fatigue, disease activity and quality of life in inflammatory bowel disease
This study investigated the efficacy of supplementation with B vitamins and magnesium in alleviating fatigue, improving disease activity, and health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) based on patient-reported outcomes. In this randomized, double-blind, placebo-controlled trial, 98 adults with IBD in remission were randomized (1:1) to receive daily supplementation with vitamins B1, B6, B12, and magnesium or a matching placebo for 4 weeks. Outcomes were assessed using validated instruments, including the Inflammatory Bowel Disease Fatigue Scale (IBD-F), Patient-reported Simple Clinical Colitis Activity Index (P-SCCAI), Simplified Crohn's Disease Activity Index (SCDAI), and the Short Inflammatory Bowel Disease Questionnaire (IBDQ-9). Compared with placebo, the intervention produced greater reductions in ulcerative colitis (UC) activity measured by P-SCCAI (β = -1.32; p = 0.006) and fatigue assessed by IBD-F Section 1 (β = -1.98; p < 0.001) and Section 2 (β = - 5.19; p < 0.001). No significant between-group differences were observed for Crohn's disease activity (SCDAI; β = -3.93; p = 0.301) or HRQoL measured by IBDQ-9 (β = 1.21; p = 0.114). Supplementation with B vitamins and magnesium improved fatigue and symptom-based disease activity scores in UC; however, effects on underlying inflammatory activity remain uncertain.
- 21 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessEffects of B vitamins and magnesium on fatigue, disease activity and quality of life in inflammatory bowel disease
This study investigated the efficacy of supplementation with B vitamins and magnesium in alleviating fatigue, improving disease activity, and health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) based on patient-reported outcomes. In this randomized, double-blind, placebo-controlled trial, 98 adults with IBD in remission were randomized (1:1) to receive daily supplementation with vitamins B1, B6, B12, and magnesium or a matching placebo for 4 weeks. Outcomes were assessed using validated instruments, including the Inflammatory Bowel Disease Fatigue Scale (IBD-F), Patient-reported Simple Clinical Colitis Activity Index (P-SCCAI), Simplified Crohn's Disease Activity Index (SCDAI), and the Short Inflammatory Bowel Disease Questionnaire (IBDQ-9). Compared with placebo, the intervention produced greater reductions in ulcerative colitis (UC) activity measured by P-SCCAI (β = -1.32; p = 0.006) and fatigue assessed by IBD-F Section 1 (β = -1.98; p < 0.001) and Section 2 (β = - 5.19; p < 0.001). No significant between-group differences were observed for Crohn's disease activity (SCDAI; β = -3.93; p = 0.301) or HRQoL measured by IBDQ-9 (β = 1.21; p = 0.114). Supplementation with B vitamins and magnesium improved fatigue and symptom-based disease activity scores in UC; however, effects on underlying inflammatory activity remain uncertain.
- Open Access
- 1 January 2026
- Published by InkVista Publishing House
- Vol. 12 (1) , 36-46
Global Burden, Trends, and Projections of Self-Harm and Interpersonal Violence: 1990–2040
- 1 January 2026
- Published by InkVista Publishing House
- Vol. 12 (1) , 36-46
Open AccessGlobal Burden, Trends, and Projections of Self-Harm and Interpersonal Violence: 1990–2040